NCT07133984Recruiting
STICH3C Cardiac Magnetic Resonance Observational Study
STICH3C Cardiac Magnetic Resonance (CMR) Observational Study (STICOS)
Source: ClinicalTrials.gov · Last updated 21 Sept 2026
Brief summary (registry, in English)
STICOS will test the hypothesis that residual jeopardized myocardium, late gadolinium enhancement, and non-ischemic substrate after revascularization is associated with postoperative adverse cardiovascular events such as heart failure , readmission, or death. This study will look at whether certain heart tissue abnormalities seen on MRI scans can help predict serious health problems after heart procedures like stents or bypass surgery.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 230 (estimated)
- First submitted
- 14 Aug 2025
- Start date
- 1 Mar 2024
- Primary completion date
- Aug 2028
- Lead sponsor
- Weill Medical College of Cornell University
- Diseases
- Coronary artery disease
- NCT number
- NCT07133984
What you commit to
- Study type: Observational
- Planned participants: 230
- From 1 Mar 2024 to the primary completion date, Aug 2028
- 10 sites in 6 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant valve disease or other condition (e.g., LV aneurysm) requiring surgical repair or replacement
Other
- Contraindication to CMR (i.e. magnetically activated materials), gadolinium, regadenoson/adenosine/dipyridamole
- Active neoplasm and/or severe end-organ dysfunction with expected life expectancy less than 5 years.
- \-
Who the study is looking for
- Men and women ≥ 18 years old
- LVEF ≤ 40% (quantified by echo, single-photon emission computed tomography \[SPECT\], or CMR within 2 months of enrollment)
- Prognostically important CAD: either multivessel CAD (triple vessel or double vessel CAD including left anterior descendant artery (LAD), significant coronary stenosis defined as ≥ 70% based on coronary angiography, fractional flow reserve (FFR) ≤ 0.80 or instantaneous wave-free ratio (iFR) ≤ 0.89) or left main disease (+/- other CAD) for which significant stenosis defined as \> 50% based on coronary angiography, intravascular ultrasound (IVUS) minimum luminal area \[MLA\] value ≤ 6.0 mm2 (\< 4.5 mm2 Asian descent), or equivalent optical coherence tomography (OCT) measurements.
- Either planned CABG/PCI within 3 months or CABG/PCI within the last 9 months.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (10)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| MU Vienna Austria Coordinator of this site? Confirm its status | Vienna | Austria | Recruiting |
| Libin Cardiovascular Institute Coordinator of this site? Confirm its status | Calgary | Canada | Recruiting |
| Universite Laval Quebec (CRIUCPQ) Canada Coordinator of this site? Confirm its status | Québec | Canada | Recruiting |
| Sunnybrook Health Sciences Centre Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
| Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
| Zbigniew Religa Lower Silesian Heart Disease Centre - Medinet Coordinator of this site? Confirm its status | Wroclaw | Poland | Recruiting |
| Dedinje Cardiovascular Institute Coordinator of this site? Confirm its status | Belgrade | Serbia | Recruiting |
| NewYork-Presbyterian Brooklyn Methodist Hospital Coordinator of this site? Confirm its status | Brooklyn | United States | Recruiting |
| New York Presbyterian Queens Coordinator of this site? Confirm its status | Flushing | United States | Recruiting |
| Weill Cornell Medicine/NewYork-Presbyterian Hospital Coordinator of this site? Confirm its status | New York | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.